Compare Bristol-Myers Squibb Co (BMY) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Coinbase Global, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Coinbase Global, Inc. trades at $163.52 (market cap $42.55B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.7× Coinbase Global, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| BMY | COIN | |
|---|---|---|
Market Cap | $116.30B | $42.55B |
Sector | Health | Technology |
52-Week High | $62.37 | $419.78 |
52-Week Low | $42.60 | $141.09 |
Enterprise Value | $152.24B | $39.83B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
COIN trades at $157.37, down 1.07% on the day, with bearish technical signals from moving averages and a neutral RSI. The company reported mixed Q1 2026 earnings, missing estimates, but maintains strong revenue growth with 2025 revenue of $7.18 billion and net income of $1.26 billion. Recent news highlights regulatory developments and a leadership transition, with the Chief Legal Officer stepping down in July 2026.
The stock presents a high-risk opportunity with Wall Street analysts maintaining a bullish consensus price target of $228.62, implying significant upside. Key risks include earnings volatility, regulatory uncertainty, and competitive pressures. Investors should weigh the company's solid cash flow generation against its elevated valuation multiples and recent earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
